Yes. Tirzepatide is a synthetic peptide medication made from a 39-amino-acid sequence. It is the active ingredient in Mounjaro and Zepbound and works as a dual GIP and GLP-1 receptor agonist. Its peptide structure helps explain why it affects appetite, fullness, gastric emptying, and blood sugar regulation 1.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic peptide, also called a synthetic polypeptide, because it is made from a chain of amino acids. StatPearls describes tirzepatide as a synthetic peptide composed of 39 amino acids that acts at both GIP and GLP-1 receptors 1.
Quick facts: tirzepatide in plain English
- Generic active ingredient: tirzepatide.
- Drug class: dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
- Common shorthand: dual agonist or twincretin.
- Brand-name products: Mounjaro and Zepbound.
- Compounded variant: compounded tirzepatide through licensed 503A pharmacies when prescribed for an individual patient.
Why a 39-amino-acid medication is considered a peptide
A peptide is a short chain of amino acids. Natural hormones such as GLP-1 and GIP are peptides made by the gut. Tirzepatide is engineered to act on the same receptor family, but it is modified so its activity lasts longer than natural gut hormones 1.
How tirzepatide differs from natural GLP-1 and GIP hormones
Natural GLP-1 and GIP rise after meals and help the body respond to food. Tirzepatide is not simply natural GLP-1 or natural GIP. It is a designed medicine that activates both receptor systems and is studied as a longer-acting treatment for type 2 diabetes and chronic weight management 1, 2.
What are Mounjaro, Zepbound, and tirzepatide?
Tirzepatide is the generic active ingredient. Mounjaro and Zepbound are brand-name products that contain tirzepatide, but their FDA-approved indications are different 2.
| Name | What it is | FDA-approved use | Important note |
|---|---|---|---|
| Tirzepatide | Generic active ingredient | Used in FDA-approved products for specific indications | Also may be prepared as a compounded medication when prescribed for an individual patient |
| Mounjaro | Brand-name tirzepatide | Improve blood sugar in adults with type 2 diabetes, with diet and exercise | Not the same product as compounded tirzepatide |
| Zepbound | Brand-name tirzepatide | Chronic weight management in adults with obesity or overweight with at least one weight-related condition, with reduced-calorie diet and increased physical activity | Not the same product as compounded tirzepatide |
| Compounded tirzepatide | A patient-specific compounded medication | Not FDA-approved | Should require a clinician’s prescription and a state-licensed pharmacy |
Zepbound was FDA-approved for adults with obesity or adults with overweight and at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol, along with a reduced-calorie diet and increased physical activity 2. Mounjaro contains tirzepatide and is approved to improve blood sugar in adults with type 2 diabetes when used with diet and exercise 2, 6.
How does a peptide like tirzepatide work in the body?
Tirzepatide works by activating two hormone receptors that help the body respond to food. These receptors are GIP and GLP-1, which are involved in appetite, fullness, insulin response, gastric emptying, and blood glucose 1, 2.
GLP-1 receptor activity: appetite, fullness, and gastric emptying
GLP-1 receptor activity helps reduce appetite and food intake. It can also slow gastric emptying, which means food leaves the stomach more slowly. That can help people feel full sooner, but it can also cause nausea, reflux, bloating, or constipation 2, 7.
GIP receptor activity: insulin response and metabolic signaling
GIP stands for glucose-dependent insulinotropic polypeptide. In plain English, it is a gut hormone that helps signal insulin release when glucose is present. Tirzepatide’s GIP activity is one reason it is different from single-receptor GLP-1 medications such as semaglutide 1, 5.
Why tirzepatide is called a dual agonist or twincretin
A receptor agonist is a medicine that turns on a receptor. Because tirzepatide turns on both GIP and GLP-1 receptors, it is called a dual agonist. Some medical reviews also call it a twincretin because it targets two incretin hormone pathways 1.
What is the difference between peptides and tirzepatide?
Peptide is a broad category; tirzepatide is one specific prescription peptide medication. Not every peptide is a weight-loss medication, and not every peptide sold online is appropriate for human use.
Some peptides are FDA-approved medicines for specific uses. Others are investigational compounds studied in animals, cells, or early human trials. Research-use-only peptides are not the same as prescription medication and should not be used for human treatment outside appropriate clinical and regulatory pathways 3.
This distinction matters because peptide products sold without a prescription may have unclear identity, potency, sterility, storage, or labeling. FDA warns patients to avoid online sellers that do not require screening and a prescription by a licensed clinician 3.
3-min quiz
Considering tirzepatide with clinician oversight?
Chia offers compounded tirzepatide tablets and injections through a 100% online process. A licensed US provider reviews your health history and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
What peptides or medications are similar to tirzepatide?
Semaglutide is the closest widely known comparison because it is also a peptide-based incretin medication. The key difference is that semaglutide acts at the GLP-1 receptor, while tirzepatide acts at both GIP and GLP-1 receptors 1, 5.
Ozempic and Wegovy are brand-name semaglutide products. Chia offers compounded semaglutide injection and compounded tirzepatide when a licensed provider finds treatment appropriate, but compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
Retatrutide and cagrilintide should be discussed carefully. FDA has stated that retatrutide and cagrilintide are not eligible for compounding under federal law and have not been found safe and effective for any condition 3. Chia does not offer them.
What does tirzepatide’s peptide structure mean for taking it?
Peptide medications are often injected because the digestive system can break peptide chains down before they reach the bloodstream. FDA labeling for brand-name tirzepatide products describes once-weekly subcutaneous injection, with dose escalation under medical direction 6, 7.
Dose changes are usually gradual because incretin medicines can cause gastrointestinal side effects. FDA labeling and clinical references describe nausea, vomiting, diarrhea, constipation, abdominal pain, burping, reflux, fatigue, injection-site reactions, hypersensitivity reactions, and hair loss among reported adverse reactions 2, 7.
Storage and handling also matter. FDA has warned about unsafe online GLP-1 sources, including products that arrive with broken packaging, missing instructions, or possible improper storage during shipping 3. A licensed pharmacy process is part of the safety system, not a minor detail.
What are the main safety points patients should know?
Tirzepatide can be useful for the right patient, but it is not right for everyone. The main safety points are gastrointestinal side effects, contraindications, drug interactions, and health conditions that need clinician review.
FDA safety information says tirzepatide should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Warnings also include pancreatitis, gallbladder problems, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury, diabetic retinopathy complications in some patients with diabetes, and suicidal behavior or thinking 2, 7.
Eating sugar while taking tirzepatide is not usually a medication emergency by itself, but large, high-fat or high-sugar meals may worsen nausea, reflux, diarrhea, or stomach discomfort for some people. Patients with diabetes also need a clinician-guided plan for blood sugar monitoring and medication adjustment, especially if they use insulin or sulfonylureas 7.
Stopping therapy can also matter. In the SURMOUNT-4 randomized withdrawal trial, adults who continued tirzepatide maintained and extended weight reduction more than those switched to placebo after an initial treatment period; individual results vary 8. This does not mean every person must stay on tirzepatide forever, but it does mean stopping should be planned with a clinician.
Tirzepatide treatment at Chia: tablets, injections, and microdosing
At Chia, compounded tirzepatide treatment starts online with a short health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is never guaranteed.
Chia offers tirzepatide tablets and injections. Plans currently start at $249/mo for tablets and $299/mo for injections, with microdosing plans available when clinically appropriate. Dosing is provider-guided and adjusted over time through your care team.
| Chia option | Form | Current starting price | How to think about it |
|---|---|---|---|
| Tirzepatide tablets | Tablet | From $249/mo | May fit patients who prefer a non-injection option, if clinically appropriate |
| Tirzepatide injection | Injection | From $299/mo | May fit patients who prefer the more common peptide-medication route |
| Weight + Energy | NAD+ Injection + choice of GLP-1 | From $309/mo | A multi-treatment protocol for eligible patients with weight and energy goals |
| Weight + Muscle | Sermorelin Injection + choice of GLP-1 | From $329/mo | A multi-treatment protocol for eligible patients with weight and muscle-support goals |
For patients whose goals include energy or body-composition support, our providers may discuss protocols such as Weight + Energy or Weight + Muscle if they fit the person’s health history and goals. These are clinician-reviewed options, not automatic add-ons.
How should patients think about compounded tirzepatide?
Compounded tirzepatide is a prescription medication prepared for an individual patient by a compounding pharmacy. It is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing 3.
The safety line we focus on is licensed versus unlicensed. A legitimate path includes a medical review by a licensed clinician, a real prescription, and dispensing by a state-licensed pharmacy. FDA warns patients about online sellers that skip screening, sell products without prescriptions, make “same as” claims, or ship products with damaged packaging or missing instructions 3.
Compounded tirzepatide should not be described as a generic version of Mounjaro or Zepbound, and it should not be treated as interchangeable with those brands. When we discuss trial results, those results belong to tirzepatide as studied in the trial or FDA-reviewed product, not to every compounded formulation.
3-min quiz
Start with a licensed-provider review
If you want to understand whether tirzepatide treatment at Chia may fit your health history, start with the online eligibility quiz. A licensed provider reviews your information, dosing is provider-guided, and medications are compounded by US state-licensed 503A pharmacies and shipped to your door when prescribed. A prescription is not guaranteed.
Frequently asked questions
It is both peptide-based and GLP-1 related. Tirzepatide is a synthetic peptide that activates GLP-1 receptors and GIP receptors, so it is more specific to call it a dual GIP/GLP-1 receptor agonist.
Yes. Zepbound contains tirzepatide, which is a synthetic peptide medication. Zepbound is FDA-approved for chronic weight management in certain adults, along with reduced-calorie diet and increased physical activity.
Yes. Mounjaro contains tirzepatide, a synthetic peptide. Mounjaro is FDA-approved to help improve blood sugar in adults with type 2 diabetes when used with diet and exercise.
No. Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide activates the GLP-1 receptor. They are related incretin-based medications, but they are different active ingredients.
Eating sugar is not usually dangerous by itself, but high-sugar or high-fat meals may worsen nausea, reflux, diarrhea, or stomach discomfort for some people. People with diabetes should follow their clinician’s plan for blood sugar monitoring.
Not everyone stays on tirzepatide forever, but stopping can lead to weight regain for some people. A clinician can help plan maintenance, tapering, or a transition strategy based on your goals and health history.
No. Research-use-only peptides are not meant for human treatment. Tirzepatide should be used only through a licensed clinician and an appropriate pharmacy.
No. Compounded tirzepatide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or quality before marketing. It should require a prescription from a licensed clinician and dispensing by a state-licensed pharmacy.
References
- 1.Min T, Bain SC. Tirzepatide. StatPearls. 2026.
- 2.U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. 2023.
- 3.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025.
- 4.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 5.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- 6.U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2022.
- 7.U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
- 8.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
